Pharma Medical News

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

FDA Approves New Medtronic Left Heart Lead for Cardiac Resynchronization Therapy Devices
Medtronic, 05/07/09

Medtronic, Inc. announced U.S. Food and Drug Administration approval and availability of the Attain Ability left-heart lead for use with cardiac resynchronization therapy devices for heart failure patients. Attain Ability has the thinnest lead body of any left-heart lead currently available, providing physicians with a tool to deliver therapy directly to hard-to-reach areas of the heart. Attain Ability incorporates insulation material developed by NASA Langley Research Center that was previously evaluated for space applications, high-performance engines and harsh environments. This application marks the first time a NASA-developed material has been used in this kind of implantable medical device.

<< Previous
Biovail Announces Acquisition of U.S. Rights to Wellbutrin XL

Next >>
LeClerc Foods Announces a Limited Nationwide Voluntary Recall of...